№ of patients | Effect | Certainty | Importance | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
№ of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | fasting regimens | energy restricted or usual intake | Relative (95% CI) | Absolute (95% CI) | ||
Adiponectin (follow-up: range 4 weeks to 64 weeks; assessed with Kit) | ||||||||||||
12 | randomised trials | not serious | not serious | not serious | seriousa | all plausible residual confounding would reduce the demonstrated effect | 211 | 197 | - | MD 0.41 0.41 higher (0.07 lower to 0.89 higher) | ⨁⨁⨁⨁ Higha | CRITICAL |
Leptin (follow-up: range 3 weeks to 64 weeks; assessed with: Kit) | ||||||||||||
15 | randomised trials | not serious | not serious | not serious | seriousb | strong association all plausible residual confounding would reduce the demonstrated effect | 292 | 284 | - | MD 2.65 2.65 lower (3.86 lower to 1.44 lower) | ⨁⨁⨁⨁ Highb | CRITICAL |
Ghrelin (follow-up: range 6 weeks to 8 weeks; assessed with: Kit) | ||||||||||||
3 | randomised trials | not serious | seriousc | not serious | Seriousd | very strong association all plausible residual confounding would reduce the demonstrated effect | 57 | 55 | - | MD 0.57 0.57 lower (1.01 lower to 0.03 lower) | ⨁⨁⨁⨁ moderatec,d | IMPORTANT |